Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

Gut microbes regulate brain levels of serotonin

UCC scientists have shown that brain levels of serotonin, the 'happy hormone' are regulated by the amount of bacteria in the gut during early life. Their research is being published today in the leading international psychiatry journal, Molecular Psychiatry.

13 Jun 2012

Unnecessary medical imaging can reduce risk of breast cancer in women

A report issued by the Institute of Medicine (IOM) last December reviewed all the available scientific data compiled to date about potential environmental risks of breast cancer-factors such as pesticides, beauty products, household chemicals, and the plastics used to make water bottles.

12 Jun 2012

Updated AAN guideline outlines treatments for infantile spasms

The American Academy of Neurology has issued an updated guideline outlining the best treatments for infantile spasms, a rare type of seizure that can occur in infants and young children.

12 Jun 2012

IVF linked to increased relapse rate among MS patients

In vitro fertilisation (IVF) is linked to an increased rate of relapse among women with multiple sclerosis (MS), suggests a small study published online in the Journal of Neurology Neurosurgery and Psychiatry.

12 Jun 2012

Increased risk of brain aneurysm linked to early menopause

The younger a woman is when she goes through the menopause, the greater may be her risk of having a brain (cerebral) aneurysm, suggests research published online first in the Journal of NeuroInterventional Surgery.

12 Jun 2012

RGS proteins play an essential role in night blindness

In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute have identified several proteins that help regulate cells' response to light-and the development of night blindness, a rare disease that abolishes the ability to see in dim light.

12 Jun 2012

Menopausal women with high oestradiol levels at greater risk of strokes

Women are less prone to cardiovascular disease then men; but this difference between the sexes becomes less marked after the menopause. This observation is behind a great deal of received wisdom, where oestrogen is assumed to have a beneficial effect on the heart and blood vessels.

11 Jun 2012

Epo has performance-enhancing effect on brain, may help treat depression, schizophrenia

Sportsmen and women dope with the blood hormone Epo to enhance their performance. Researchers from the University of Zurich now discovered by animal testing that Epo has a performance-enhancing effect in the brain shortly after injection and not only after days by improving oxygen transport in blood. As Epo also increases motivation, it could be useful in treating depression.

11 Jun 2012

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Sanofi announced today that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c - glycated hemoglobin - reduction with Lantus (insulin glargine [rDNA origin] injection) versus sitagliptin.

11 Jun 2012

Amylin announces results from SYMLIN clinical studies on type 2 or 1 diabetes

Amylin Pharmaceuticals, Inc. today announced results from new analyses of previously completed clinical studies demonstrating that patients with type 2 or type 1 diabetes achieved a greater proportion of blood glucose measurements in the normal range when SYMLIN (pramlintide acetate) injection treatment was used along with insulin.

11 Jun 2012

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin Pharmaceuticals, Inc. and Alkermes plc today announced results from the long-term extension of the DURATION-1 study, which showed that BYDUREON (exenatide extended-release for injectable suspension), the first and only once-weekly treatment for type 2 diabetes, was associated with clinically significant and sustained improvements in glycemic control during four years of treatment in adults with type 2 diabetes.

11 Jun 2012

Lilly, Boehringer Ingelheim announce results from linagliptin Phase III trial on T2D

Boehringer Ingelheim and Eli Lilly and Company presented results from a randomised Phase III clinical trial and a post-hoc analysis for linagliptin at ADA.

11 Jun 2012

Genetic influence on postmenopausal bone loss falls with age

The effect of genetics on bone loss rates in postmenopausal women reduces until the age of 65 years, after which time its influence disappears completely, according to results from a twin-based study.

8 Jun 2012

Positive results from Amgen Sensipar/Mimpara Phase 3 trial for HPT, CKD

Amgen today announced top-line results of the Phase 3 EVOLVE (EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events) trial, which evaluated Sensipar/Mimpara (cinacalcet) for the reduction of the risk of mortality and cardiovascular (CV) events among 3,883 patients with secondary hyperparathyroidism (HPT) and chronic kidney disease (CKD) receiving dialysis.

8 Jun 2012

Study packs powerful one-two punch in the fight against heart failure

A new study in the journal Circulation packs a powerful one-two punch in the fight against heart failure. The leading blow: Identification of a unique alliance of proteins that plays a major role in the development of the disease. The second but equally powerful hit: Drugs that interfere with this axis already exist.

8 Jun 2012

Patients over 45 years with history of early menopause 50% less likely to develop severe RA

A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that early menopause predicts a milder form of rheumatoid arthritis (RA).

8 Jun 2012

Tp53 genetic mutation may play an important role in prostate cancer

A team of UC Davis investigators has found that a genetic mutation may play an important role in the development of prostate cancer. The mutation of the so-called p53 (or Tp53) gene was previously implicated in late disease progression, but until now has never been shown to act as an initiating factor. The findings may open new avenues for diagnosing and treating the disease.

8 Jun 2012

BD, JDRF partner to accelerate development of glucose-sensing technology for T1D

JDRF and BD today announced an extension of their existing collaboration focused on Type 1 diabetes (T1D) to accelerate the development of BD's proprietary glucose-sensing technology which has shown promise in providing very accurate and reliable continuous glucose information.

From BD (Becton, Dickinson and Company) 8 Jun 2012

Researchers identify brain receptor that appears to play a central role in regulating appetite

Researchers at Columbia University Medical Center (CUMC) have identified a brain receptor that appears to play a central role in regulating appetite. The findings, published today in the online edition of Cell, could lead to new drugs for preventing or treating obesity.

8 Jun 2012